· Regulation · Regulation Desk
Latham and Watkins' analysis of the July PCAC meeting frames two regulatory tracks moving in opposite directions: research peptides reconsidered for 503A compounding, compounded GLP-1s squeezed out.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.